hematopoietic system
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2
|
• in the bone marrow of tamoxifen-treated mice
|
• few early T cell progenitors in the thymus of tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• reduced 7-fold in tamoxifen-treated mice
|
• in the bone marrow of tamoxifen-treated mice
• however, the number of B cells in the spleen, lymph node and peripheral blood is normal
|
• to one-fifth of wild-type levels in the bone marrow of tamoxifen-treated mice
|
• in the bone marrow of tamoxifen-treated mice
|
• reduced LSK and lymphoid-primed multipotent progenitors in tamoxifen-treated mice
|
• tamoxifen-treated LSK cells exhibit a complete loss of lymphoid development
|
cellular
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2
|
immune system
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2
|
• complete loss of lymphoid development in tamoxifen-treated bone marrow cells is cell autonomous
|
• in the bone marrow of tamoxifen-treated mice
|
• few early T cell progenitors in the thymus of tamoxifen-treated mice
|
• in tamoxifen-treated mice
|
• in the bone marrow of tamoxifen-treated mice
• however, the number of B cells in the spleen, lymph node and peripheral blood is normal
|
• to one-fifth of wild-type levels in the bone marrow of tamoxifen-treated mice
|
• in the bone marrow of tamoxifen-treated mice
|
endocrine/exocrine glands
• in tamoxifen-treated mice
|